Nivolumab/Ipilimumab Yields Sustained Responses in Advanced HCC
A long-term survival benefit was consistently observed when nivolumab (Opdivo) and ipilimumab (Yervoy) were combined to treat patients with advanced hepatocellular carcinoma (HCC), according to 5-year results from the phase 1/2 CheckMate 040 trial ( …